Effect of Raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis

American Journal of Cardiology

Volumn 97, Issue 4, 2006, Pages 520-527

  Ensrud, Kristine ^a   Riccardo Genazzani, Andrea ^b   Geiger, Mary Jane ^c   McNabb, Michelle ^c   Dowsett, Sherie A ^c   Cox, David A ^c   Barrett Connor, Elizabeth ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; PLACEBO; RALOXIFENE;

AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE;

EID: 31944446656     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.09.083     Document Type: Article

References (11)

1. S. Martino, J.A. Cauley, E. Barrett-Connor, T.J. Powles, J. Mershon, D. Disch, R.J. Secrest, S. Cummings CORE Investigators Continuing Outcomes Relevant to Evista breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 2004 1751 1761
2. R.S. Blumenthal, B. Baranowski, S.A. Dowsett Cardiovascular effects of raloxifene the arterial and venous systems Am Heart J 147 2004 783 789
3. E. Barrett-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.A. Cox, K. Hoszowski, P. Rautaharju, K.D. Harper Raloxifene and cardiovascular events in osteoporotic postmenopausal women four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial JAMA 287 2002 847 857
4. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, C. Christiansen, P.D. Delmas, J.R. Zanchetta, J. Stakkestad Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial JAMA 282 1999 637 645
5. L. Mosca, E. Barrett-Connor, N.K. Wenger, P. Collins, D. Grady, M. Kornitzer, E. Moscarelli, S. Paul, T.J. Wright, J.D. Helterbrand, P.W. Anderson Design and methods of the Raloxifene Use for The Heart (RUTH) study Am J Cardiol 88 2001 392 395
6. J.E. Manson, J. Hsia, K.C. Johnson, J.E. Rossouw, A.R. Assaf, N.L. Lasser, M. Trevisan, H.R. Black, S.R. Heckbert, R. Detrano Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
7. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan Effects of conjugated equine estrogen in postmenopausal women with hysterectomy the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
8. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
9. R.S. Braithwaite, R.T. Chlebowski, J. Lau, S. George, R. Hess, N.F. Col Meta-analysis of vascular and neoplastic events associated with tamoxifen J Gen Intern Med 18 2003 937 947
10. C.D. Bushnell, L.B. Goldstein Risk of ischemic stroke with tamoxifen treatment for breast cancer a meta-analysis Neurology 63 2004 1230 1233
11. S. Martino, D. Disch, S.A. Dowsett, C.A. Keech, J.L. Mershon Safety assessment of raloxifene over eight years in a clinical trial setting Curr Med Res Opin 21 2005 1441 1452